PCR statement on the future of paclitaxel drug-coated balloons
Summary
Up until December 2018, drug-coated balloons (DCBs) were considered the standard of care in superficial femoral artery (SFA) disease. However, a meta-analysis published by Katsanos and colleagues in JAHA in 2018 has challenged the safety of paclitaxel DCBs for that indication. Should physicians therefore change their clinical practice based on the conclusions of this meta-analysis? Alexandra Lansky explains the controversy surrounding the use of paclitaxel DCBs to Eugenio Stabile…